Stockman, I am sure he has enough data (hope it is positive):...

Stockman, I am sure he has enough data (hope it is positive): the open study interim results so far. He can add it to his poster, which could have a list about how ATH434 reduced alpha-synuclein in both MSA and PS animal models, with just one new line on the poster: human MSA population.

Correspondingly Claassen could add what happens in NFL MSA patients who are treated with ATH434 demonstrating that Nfl measure is not only positively correlated with the worsening of the symptoms but also demonstrates improvement of the symptoms ( as I believe to be the case).

These small changes are new info also to us, as new info was promised on the 20th of Feb when AAN poster presentations were informed.

The main issue of the open study is the iron content of the brain and I believe that in that measure we have at this time still not enough cases ( 6 months of treatment). So for that result, we need to wait, but for alpha-synuclein and Nfl there is at least a 3-month result from almost all 15 cases but less 6-month measurements. All animal studies lasted only a maximum of 3 months.

So the primary outcome measure, brain iron is missing and we need to wait until June, but it does not harm if synuclein and Nfl act as we believe and are correlated with the symptom.